Alex Adjei, MD
The Cleveland Clinic · Roswell Park Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Alex Adjei, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:58 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT03647163 · Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid TumorsVyriad, Inc. · active not recruiting · Solid Tumor, Non Small Cell Lung Cancer, Neuroendocrine Carcinoma · principal investigator
- Ph1/Ph2NCT01188499 · Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid TumorsTetraLogic Pharmaceuticals · completed · Cancer · principal investigator
- Ph1NCT00993239 · Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or LymphomaTetraLogic Pharmaceuticals · completed · Cancer · principal investigator
- Ph2NCT00750698 · A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on ErlotinibSyndax Pharmaceuticals · terminated · Non Small Cell Lung Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:58 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in non-small cell lung cancer.